U.S. Markets close in 4 hrs 50 mins
  • S&P 500

    3,620.88
    +43.29 (+1.21%)
     
  • Dow 30

    29,960.87
    +369.60 (+1.25%)
     
  • Nasdaq

    11,982.36
    +101.72 (+0.86%)
     
  • Russell 2000

    1,848.35
    +30.06 (+1.65%)
     
  • Crude Oil

    44.84
    +1.78 (+4.13%)
     
  • Gold

    1,802.80
    -35.00 (-1.90%)
     
  • Silver

    23.19
    -0.44 (-1.85%)
     
  • EUR/USD

    1.1879
    +0.0034 (+0.2851%)
     
  • 10-Yr Bond

    0.8750
    +0.0180 (+2.10%)
     
  • Vix

    22.11
    -0.55 (-2.43%)
     
  • GBP/USD

    1.3354
    +0.0032 (+0.2390%)
     
  • USD/JPY

    104.6420
    +0.1540 (+0.1474%)
     
  • BTC-USD

    19,343.68
    +891.71 (+4.83%)
     
  • CMC Crypto 200

    383.26
    +13.51 (+3.65%)
     
  • FTSE 100

    6,414.37
    +80.53 (+1.27%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

FDA approves Horizon's drug for thyroid eye disease

Jan 21 (Reuters) - The U.S. Food and Drug Administration has approved Horizon Therapeutics Plc's treatment for thyroid eye disease, the agency said on Tuesday.

The decision makes teprotumumab the first approved treatment for the vision-threatening autoimmune disorder, in which the muscles and fatty tissue behind the eye become inflamed and expand. (Reporting by Vishwadha Chander and Dania Nadeem; Editing by Arun Koyyur)